Burning Rock Biotech (NASDAQ:BNR – Get Free Report) and Korro Bio (NASDAQ:KRRO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.
Earnings and Valuation
This table compares Burning Rock Biotech and Korro Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Burning Rock Biotech | $77.16 million | 1.78 | -$7.92 million | ($0.87) | -15.02 |
| Korro Bio | $1.29 million | 132.16 | -$117.26 million | ($9.06) | -1.37 |
Burning Rock Biotech has higher revenue and earnings than Korro Bio. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Burning Rock Biotech and Korro Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Burning Rock Biotech | -13.60% | -12.98% | -8.59% |
| Korro Bio | N/A | -117.06% | -69.74% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Burning Rock Biotech and Korro Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Burning Rock Biotech | 1 | 0 | 0 | 0 | 1.00 |
| Korro Bio | 1 | 0 | 6 | 3 | 3.10 |
Korro Bio has a consensus price target of $17.29, indicating a potential upside of 38.95%. Given Korro Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Korro Bio is more favorable than Burning Rock Biotech.
Insider & Institutional Ownership
30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Burning Rock Biotech has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3.23, suggesting that its stock price is 223% more volatile than the S&P 500.
Summary
Korro Bio beats Burning Rock Biotech on 8 of the 15 factors compared between the two stocks.
About Burning Rock Biotech
Burning Rock Biotech is a precision oncology company that develops and provides next-generation sequencing tests for cancer. Its testing uses tissue and blood samples to help inform treatment decisions, monitor disease and support cancer research. The company also provides research and clinical-trial services to pharmaceutical companies, including support for the development of cancer therapies and diagnostic tests. Burning Rock is headquartered in Guangzhou, China, and its business primarily serves the Chinese healthcare and life sciences markets.
About Korro Bio
Korro Bio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. It develops RNA-editing medicines intended to address genetic diseases by changing specific RNA sequences rather than altering a patient’s DNA. The company’s OPERA platform uses oligonucleotides to direct the body’s naturally occurring ADAR enzymes to edit targeted RNA. Korro has developed KRRO-110, an investigational candidate designed to correct a disease-associated RNA change linked to alpha-1 antitrypsin deficiency.
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
